Wockhardt Limited (NSE:WOCKPHARMA)
India · Delayed Price · Currency is INR | Market Cap | 193.28B -10.6% |
| Revenue (ttm) | 31.74B +5.8% |
| Net Income | 220.00M |
| EPS | 1.34 |
| Shares Out | 162.49M |
| PE Ratio | 878.57 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 999,098 |
| Average Volume | 600,193 |
| Open | 1,190.00 |
| Previous Close | 1,197.20 |
| Day's Range | 1,164.40 - 1,218.00 |
| 52-Week Range | 1,086.70 - 1,868.80 |
| Beta | 0.68 |
| RSI | 40.76 |
| Earnings Date | May 30, 2026 |
About Wockhardt
Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical and biotech company, in India, the United States, the United Kingdom, Switzerland, Ireland, Russia, Europe, and internationally. It manufactures and trades pharmaceuticals, medicinal chemical, and botanical products, as well as chemicals and chemical products. The company also develops its flagship antibiotic, ZAYNICH zidebactam/cefepime, a novel beta lactam enhancer mechanism for the treatment of sepsis and hospital/ventilator associated pneumonia; FOVISCU, an anti... [Read more]
Financial Performance
In fiscal year 2025, Wockhardt's revenue was 30.35 billion, an increase of 7.24% compared to the previous year's 28.30 billion. Losses were -470.00 million, -89.85% less than in 2024.
Financial StatementsNews
Pharma sector stocks today, March 25: Wockhardt surge 7.40%, Senores Pharma up 5.95%, Natco Pharma jumps 3.32%
Several pharmaceutical stocks traded higher in early morning sessions on the BSE and NSE. The S&P BSE Healthcare Index stood at 42,461.1, reflecting a gain of 1.4% for the day.…
Pharma sector stocks rally sharply today, March 25: Wockhardt surge 7.40%, Senores Pharma up 5.95%, Natco Pharma jumps 3.32%
Several pharmaceutical stocks traded higher in early morning sessions on the BSE and NSE. The S&P BSE Healthcare Index stood at 42,461.1, reflecting a gain of 1.4% for the day.…
Pharma sector stocks today, March 6: Shilpa Medicare surge 3.08%, Wockhardt jumps 2.12%, Natco Pharma up 1.84%,
The pharmaceutical sector in India showed mixed performance on March 6, 2026, during early trading hours. Data from around 9:46 AM to 9:50 AM IST indicated the S&P BSE HEALTHCARE…
Wockhardt shares in focus after Phase 3 success of novel antibiotic Foviscu
Shares of Wockhardt are likely to be in focus after the company announced positive results from a pivotal Phase 3...
Wockhardt files Marketing Authorisation Application to EMA for antibiotic WCK 5222
Wockhardt has taken a significant step in global pharmaceutical innovation by successfully filing a Marketing Authorisation Application (MAA) with the...
Wockhardt shares in spotlight after EMA grants accelerated assessment to WCK 5222
Shares of Wockhardt are likely to remain in focus on Wednesday, December 31, after the company announced that the European...
Wockhardt shares rally sharply over 9% as US FDA accepts NDA for breakthrough antibiotic Zaynich
Wockhardt Ltd. recorded a sharp rally of more than 9% after announcing a significant regulatory breakthrough: the United States Food...
Wockhardt secures historic US FDA acceptance for antibiotic Zaynich
Wockhardt Ltd. has achieved a historic milestone with the United States Food and Drug Administration formally accepting the New Drug...
Wockhardt submits NDA to US FDA for novel antibacterial Zidebactam-Cefepime
Wockhardt Ltd. has announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (US FDA) for its novel antibacterial agent, Zidebactam-Cefepime injection (WCK 5222...
Wockhardt shares fall over 5% after Trump’s pharma tariff announcement
Shares of Wockhardt Ltd slumped 4.93% to ₹1,403.30 on Friday, September 26, after U.S. President Donald Trump announced a 100% tariff on branded and patented pharmaceutical imports, effective October ...
Shukra Pharmaceuticals secures Pan-India distribution rights from Wockhardt
Shukra Pharmaceuticals Limited has been granted non-exclusive rights by Wockhardt Limited for distributing products across all ESIC/ESIS and Defence hospitals in India. The agreement, valid till March...
Wockhardt Q1 Results: Shares drop 3% as EBITDA falls 20.9% YoY Rs 72 crore, revenue flat at Rs 739
Wockhardt shares came under pressure in Friday’s session, falling over 3% after the company posted disappointing Q1 FY26 results. As of 2:24 PM, the shares were trading 2.85% lower at Rs 1,478.40. The...
Wockhardt shares jump 4% after exiting loss-making US generics business
Wockhardt shares jumped 4% after the company announced a major strategic shift in its US operations. The pharma firm is exiting the US generic drug market to focus on high-value, research-driven areas...
Wockhardt exits US generics business to focus on innovative portfolio
Wockhardt has announced a major strategic shift in its US operations, marking a significant step in its journey to become a future-ready, innovation-driven pharmaceutical company. As part of this real...
Senores Pharmaceuticals acquires USFDA-approved ANDA for Enalapril Maleate Tablets from Wockhardt
Senores Pharmaceuticals Limited (SPL), through its wholly-owned US subsidiary, Senores Pharmaceuticals, Inc. (SPI), has entered into an agreement to acquire the USFDA-approved Abbreviated New Drug App...
Senores Pharmaceuticals share price jumps 3% after company acquires ANDA for Topiramate tablets from Wockhardt
Senores Pharmaceuticals’ shares surged over 3% in early trading today after the company, through its wholly-owned U.S. subsidiary Senores Pharmaceuticals, Inc. (SPI), announced the acquisition of the ...
Senores Pharmaceuticals acquires ANDA for Topiramate tablets from Wockhardt
Senores Pharmaceuticals Limited (SPL), through its wholly-owned U.S. subsidiary Senores Pharmaceuticals, Inc. (SPI), has entered into an agreement to acquire the USFDA-approved Abbreviated New Drug Ap...
Wockhardt shares climb 3% as breakthrough antibiotic Zaynich™ saves US cancer patient with drug-resistant infection
Shares of Wockhardt Ltd surged nearly 3% to ₹1,466.70 in early trade on Monday after the company announced a critical success in the compassionate use of its investigational antibiotic Zaynich™ (Zideb...
Wockhardt’s novel antibiotic Zaynich™ helps save US child cancer patient battling superbug infection
Wockhardt Limited has announced a significant breakthrough in the treatment of drug-resistant infections, as its proprietary antibiotic Zaynich™ (Zidebactam/Cefepime, WCK 5222) successfully cured a 15...
Wockhardt reports Q3 Results: Revenue up 3% to Rs 721 crore, Net profit at Rs 20 crore vs loss of Rs 86 crore YoY
Pharmaceutical major Wockhardt Limited reported its financial results for the quarter ending December 31, 2024, showcasing a remarkable turnaround in profitability. The company posted a net profit of ...
Wockhardt shares surge 10% as flagship antibiotic Zaynich demonstrates breakthrough clinical success
Wockhardt Limited witnessed a 10% surge in its share price after its flagship antibiotic, Zaynich® (Zidebactam/Cefepime, WCK 5222), achieved a major milestone in clinical trials. The drug demonstrated...
Wockhardt’s Zaynich achieves 96.8% clinical cure rate, sets new benchmark in Phase III global study
Wockhardt Limited’s flagship antibiotic, Zaynich® (Zidebactam/Cefepime, WCK 5222), has achieved a significant milestone in its development, delivering the highest-ever efficacy among FDA-approved nove...
Wockhardt’s Zaynich achieves 97% efficacy in treating resistant infections
Wockhardt Limited has announced that its proprietary antibiotic combination, Zaynich® (Zidebactam/Cefepime, WCK 5222), demonstrated over 97% clinical efficacy in a pivotal study targeting carbapenem-r...
Wockhardt shares surge nearly 5% after CDSCO approval for revolutionary antibiotic Miqnaf
Shares of Wockhardt Limited climbed by nearly 5% to ₹1,515 after the company announced the approval of its novel oral antibiotic, Miqnaf® (Nafithromycin), by the Central Drugs Standard Control Organiz...
Stocks in Focus Today on January 4, 2025: Wockhardt, NHPC, RITES, IRFC, Hind Zinc and more
Foreign Institutional Investors (FIIs) were key drivers of market momentum with net inflows of ₹1,506.75 crore. FIIs purchased shares worth ₹13,402.85 crore while selling shares worth ₹11,896.10 crore...